Training cohort | Validation cohort | |
---|---|---|
Number (%) | Number (%) | |
Patients total | 103 | 71 |
No of male patients | 76 (73.8%) | 53 (75.7%) |
Age, years (mean, IQR) | 62.3 (57.3–67.8) | 63.3 (57.8–69.3) |
Mean radiation dose, Gy | 70 | 70 |
Chemotherapy | ||
Cisplatin | 88 (85.4%) | 57 (80%) |
Cetuximab | 15 (14.6%) | 14 (20%) |
T-stage | ||
2 | 46 (44.7%) | 25 (35.2%) |
3 | 24 (23.3%) | 19 (26.8%) |
4 | 33 (32%) | 27 (38%) |
N-stage | ||
0 | 14 (13.6%) | 11 (15.5%) |
1 | 13 (12.6%) | 15 (21.1%) |
2 | 75 (72.8%) | 45 (63.4%) |
3 | 1 (1%) | 0 (0%) |
HPV-status | ||
Positive | 39 (37.9%) | 26 (36.6%) |
Negative | 64 (62.1%) | 45 (63.4%) |
Tumor site | ||
Oropharynx | 74 (71.8%) | 51 (71.8%) |
Hypopharynx | 29 (28.2%) | 20 (28.2%) |
Overall alcohol history score (SD) | 1.91 (1.19) | 1.72 (1.24) |
Smoking pack years, (IQR) | 22.7 (18.2–38.9) | 23.5 (19.3–41.3) |
Follow-up time (mean, IQR) | 31.5 (20.7–44.5) | 26.4 (19.8–34.1) |
Recurrence | 27 (26.2%) | 19 (27.1%) |
Metastasis | 10 (9.7%) | 18 (25.7%) |
Death | 37 (35.9%) | 22 (31.4%) |
IQR: interquartile range |